<DOC>
	<DOCNO>NCT00887562</DOCNO>
	<brief_summary>The purpose study compare efficacy two ( 2 ) different dose idebenone placebo one month period cerebral lactate concentration measure magnetic resonance spectroscopy .</brief_summary>
	<brief_title>Study Idebenone Treatment Mitochondrial Encephalopathy Lactic Acidosis &amp; Stroke-like Episodes</brief_title>
	<detailed_description>MELAS ( Mitochondrial Encephalomyopathy , Lactic Acidosis , Stroke-Like Episodes ) , progressive often devastate multisystem disorder , commonly associate mitochondrial Deoxyribonucleic acid ( mtDNA ) point mutation nucleotide 3243 . Seizures , cognitive deterioration , neurobehavioral abnormality frequent feature disease typically shortens life expectancy . Idebenone , ATP production modulator antioxidant , improve neurological function Friedreich 's ataxia , disease also associate mitochondrial dysfunction . Given effective treatment MELAS , investigator propose Phase II proof concept trial idebenone study preliminary efficacy patient MELAS A3243G mtDNA mutation , study safety tolerability patient group . The investigator propose evaluate 21 patient A3243G mitochondrial DNA mutation MELAS ( define history either seizure stroke ) . Patients receive idebenone ( 900 mg/day 2250 mg/day ) match placebo one month . The primary outcome measure cerebral lactate level measure Magnetic Resonance Spectroscopy ( MRS ) , biomarker associate disease worsen . This study help investigator determine sufficient signal proceed efficacy study . Also provide additional information safety tolerability two different dos idebenone MELAS .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Acidosis , Lactic</mesh_term>
	<mesh_term>MELAS Syndrome</mesh_term>
	<mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Diagnosis MELAS confirm A3243G mtDNA mutation , evidence central nervous system involvement ( cognitive problem , migraine , memory loss ) Cerebral lactate level equal great 5.0 i.u . baseline Patients least 8 &lt; 65 year age baseline Patients body weight &gt; 37 kg/82 lbs baseline Stable comedication/vitamins/supplements within 1 month prior baseline Patients opinion investigator able comply requirement study , include swallow study medication Negative urine pregnancy test screen baseline ( female patient childbearing potential ) Contraindication MRS ( e.g . metal implant , claustrophobia ) Stroke like event within 2 month prior baseline Treatment idebenone dose , coenzyme Q10 dose 100mg/d within 1 month prior baseline Inadequate contraception use Pregnancy and/or breastfeed Clinically significant abnormality clinical hematology biochemistry include , limited , elevation great 1.5 time upper limit normal aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) creatinine Current abuse drug alcohol Participation trial another investigational drug within last month Other factor , investigator 's opinion , excludes patient enter study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>